LONG BEACH, Calif.--(BUSINESS WIRE)--Rosacea is a very common skin condition, affecting more than 14 million Americans. Products prescribed in the treatment of rosacea represent a $137 million market, despite the lack of a topical treatment proven to effectively treat the symptoms of the disease, primarily redness and flushing.1 Now Obagi Medical Products, Inc. (Nasdaq:OMPI), a leader in topical aesthetic and therapeutic skin health systems, offers a new option for people living with rosacea - The Obagi® Rosaclear™ System. It is the first and only complete prescription-based system developed specifically for treating the signs and symptoms of rosacea. The all-in-one system is designed to effectively reduce redness and flushing, along with treating papules and pustules, to help rosacea patients achieve a clearer, calmer and more balanced-looking complexion. The Rosaclear System will be available through physicians beginning in January and will be promoted by Obagi’s dermatology and medical aesthetics sales forces.
